GlassScriptPhysician profile
Mauricio E Rodriguez
NPI 1568860419
$2,947.72
in general payments reported to CMS, 2019-2025
13 companies · $1,476 in 2025
The $1,476 reported for 2025 was more than what 90% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $103 · 2022: $20.19 · 2023: $548 · 2024: $801 · 2025: $1,476.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,616 · Education: $209.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,615.73 |
| Education | $208.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $867.79 | 2019-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Janssen Pharmaceuticals, INC | $510.33 | 2023-2025 | Invega Sustenna |
| Vanda Pharmaceuticals INC. | $358.48 | 2023-2025 | Fanapt, Hetlioz |
| Teva Pharmaceuticals USA, INC. | $317.40 | 2023-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Medical Device Business Services, INC. | $282.22 | 2025 | Vistaseal |
| Abbvie INC. | $151.25 | 2023-2025 | Vraylar |
| Alkermes, INC. | $137.15 | 2025 | Aristada, Lybalvi |
| Indivior INC. | $120.27 | 2023-2024 | Perseris |
| Supernus Pharmaceuticals, INC. | $56.61 | 2024-2025 | Qelbree |
| Neurocrine Biosciences, INC. | $43.92 | 2024-2025 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $42.57 | 2025 | Cobenfy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $39.54 | 2024-2025 | Caplyta |
| Becton, Dickinson and Company | $20.19 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mauricio Rodriguez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.